Author: Ravi Shankar

Nursing +63% to HK$56.8 million | Professional more than doubles to HK$36.0 million | Logistics +36% to HK$42.4 million

Gross profit hits a new high; operating result turns positive; net income attributable to equity holders of HK$14.6 million

Hong Kong, Oct. 22, 2026 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), a leader in human resources (“HR”) and senior care solutions in Hong Kong, today announced record results for the fiscal year ended June 30, 2026 (“FY2026”), concurrent with the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission.

Financial highlights

• Revenue of HK$135.2 million, up 61.9% year over year, and more than three times the HK$44.1 million reported for the year ended December 31, 2023.
• Every segment at a record high: nursing HK$56.8 million (+62.6%), professional HK$36.0 million (+108.2%), logistics HK$42.4 million (+35.5%).
• Gross profit of HK$21.6 million, up 68.9%, a new high. Gross margin improved to 16.0% from 15.3% for the year ended June 30, 2025 (“FY2025”).
• Operating expenses declined to HK$20.8 million from HK$21.3 million for FY2025, with general and administrative expenses down to HK$19.2 million from HK$20.6 million for FY2025.
• Operating income of HK$0.83 million, against an operating loss of HK$8.5 million in the prior year.
• Net income attributable to equity holders of the Company of HK$14.59 million (US$1.87 million), against a loss of HK$7.93 million for FY2025.
• Basic and diluted earnings per share of HK$1.88 (US$0.24), against a loss of HK$12.55 per share for FY2025.

The following graph sets forth the Group’s total revenue for the year ended December 31, 2023, FY2025 and FY2026:

The following graph sets forth the Group’s net income (loss) for the year ended December 31, 2023, FY2025 and FY2026:

The following graph sets forth the Group’s basic and diluted earnings (loss) per ordinary share for the year ended December 31, 2023, FY2025 and FY2026:

Revenue increased 61.9% to HK$135.2 million (US$17.3 million), from HK$83.5 million in FY2025. Every reportable segment set a new revenue high. The Company swung from an operating loss of HK$8.5 million in FY2025 to operating income of HK$0.83 million, and from a net loss attributable to equity holders of HK$7.93 million in FY2025 to net income attributable to equity holders of HK$14.59 million (US$1.87 million).

The following graph sets forth the Group’s revenue by segments for the year ended December 31, 2023, FY2025 and FY2026:

Segment performance

Nursing solution services. Revenue rose 62.6% to HK$56.8 million and is now the Group’s largest segment, at 42% of revenue. Service hours reached 465,440, from 322,211 in FY2025 and 110,871 in the year ended December 31, 2023. The Company continued to build its higher-margin private-case franchise alongside its Community Care Service Voucher (CCSV) business, and during the year and up to the date of this release rolled out premium escort services and rehabilitation services. Management believes Click is one of the most comprehensive providers under the CCSV scheme. Growth from here is expected to come from a larger share of private-case work, selective mergers and acquisitions, and expansion into Mainland China.

Logistics and other solution services. Revenue rose 35.5% to HK$42.4 million, and the high growth rate is extending into fiscal 2026/27. Service hours reached 476,644, from 354,806 and 206,519 in the two earlier periods. The segment continued to win business from established Hong Kong clients and remains a reliable generator of income that funds investment in nursing.

Professional solution services. Revenue more than doubled to HK$36.0 million, up 108.2%, with a new acquisition contributing a substantial part of the increase. Management continues to look for further mergers and acquisitions in high-margin professional services.

The following graph sets forth the Group’s service hours for its nursing solution services for the year ended December 31, 2023, FY2025 and FY2026:

The following graph sets forth the Group’s service hours for its logistics and other solution services for the year ended December 31, 2023, FY2025 and FY2026:

Service hours

Nursing and logistics together delivered approximately 942,000 service hours in FY2026, against approximately 677,000 in the prior year and approximately 317,000 in the year ended December 31, 2023. The increase in nursing hours includes Care U, consolidated after January 2025.

Outlook

The outlook is bright. We are putting ongoing effort into expanding our silver economy services, including a rehabilitation centre, premium private-case offerings, and geographical expansion into Mainland China and beyond. All three segments continue to expand, and management expects the momentum in nursing, logistics, and professional services to carry into fiscal 2026/27.

Management commentary

Jeffrey Chan, Founder and Chief Executive Officer of Click Holdings, said: “FY2026 was a record year across the Group. Revenue, service hours, gross profit and net income all reached new highs, and every segment delivered its highest revenue yet. Nursing is our growth engine, logistics continues to scale and fund that growth, and professional services has returned to strong expansion through a focused acquisition. We thank our workers and our shareholders. A fuller CEO statement will follow.”

About Click Holdings Limited (NASDAQ: CLIK)

Click Holdings Limited (NASDAQ: CLIK) is a Hong Kong-based leader in AI-powered human resources and senior care solutions. Through its proprietary platform, CLIK connects clients with a talent pool of over 25,000 professionals, serving nursing, logistics, and professional services sectors.

For more information, please visit https://clickholdings.com.hk.

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For enquiry, please contact:

Click Holdings Limited

Unit 1709-11, 17/F
Tower 2, The Gateway
Harbour City, Kowloon
Hong Kong
Email: ir@clicksc.com.hk
Phone: +852 2691 8200 

22 October 2026

LEI: 2138003QW2ZAYZODBU23

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE COPPER 3X DAILY LEVERAGED SECURITIES
(ISIN: IE00B8JVMZ80)
WISDOMTREE COPPER 3X DAILY SHORT SECURITIES
(ISIN: XS3306516959)
WISDOMTREE GOLD 3X DAILY LEVERAGED SECURITIES
(ISIN: IE00B8HGT870)
WISDOMTREE GOLD 3X DAILY SHORT SECURITIES
(ISIN: IE00B6X4BP29)
WISDOMTREE NATURAL GAS 3X DAILY LEVERAGED SECURITIES
(ISIN: XS2819843900)
WISDOMTREE SILVER 3X DAILY LEVERAGED SECURITIES
(ISIN: XS3306516876)
WISDOMTREE SILVER 3X DAILY SHORT SECURITIES
(ISIN: XS3306517924)
WISDOMTREE PALLADIUM 2X DAILY LEVERAGED SECURITIES
(ISIN: IE00B94QLN63)
(THE “AFFECTED SECURITIES”)

PROPOSALS FOR THE INTRODUCTION OF AN OVERNIGHT RESTRIKE MECHANIC, A DISCRETIONARY INDEX CHANGE MECHANIC AND INCREASES TO THE SEVERE DISRUPTION EVENT THRESHOLD AND TO THE SEVERE OVERNIGHT GAP EVENT THRESHOLD IN RESPECT OF THE AFFECTED SECURITIES
MEETINGS OF THE ETP SECURITYHOLDERS

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser.

If you have sold or transferred all of your Affected Securities of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or stockbroker, banker or other agent through whom the sale or transfer was made, for onward transmission to the purchaser or transferee.

The Issuer wishes to announce that the Meetings of the holders of the Affected Securities scheduled for 22 October 2026 at 9:00 a.m. and onwards (the “Original Meetings”) have been adjourned, in accordance with paragraph 20 of Schedule 7 of the Trust Deed, for lack of a quorum. The adjourned meeting will be reconvened at 9:00 a.m. and onwards on 3 December 2026, being a date not less than 14 nor more than 42 calendar days after the Original Meeting, and will be held at the offices of Apex IFS Limited in 2nd Floor, Block 5, Irish Life Centre, Abbey Street Lower, Dublin 1, D01P767, Ireland (the “Adjourned Meeting”).

The Adjourned Meeting is being held to consider certain amendments, made under the powers set out in paragraph 2 of Schedule 7 of the Master Trust Deed of the Affected Securities, to documentation required to effect proposals for the introduction of an overnight restrike mechanic, a discretionary index change mechanic and increases to the Severe Disruption Event Threshold and to the Severe Overnight Gap Event Threshold in respect of the affected securities.

Under article 11.5 of the Issuer’s Articles of Association, no further notification is required for the Adjourned Meeting. Holders of the Affected Securities are therefore directed to the original notification, including the circular dated 29 September 2026, and also a revised form of proxy for the Adjourned Meeting, which are available on the website of the Issuer at the below link.

Circular: https://www.wisdomtree.com/gb/media/wtma-circular-platform-29-september-2026

Proxy: https://www.wisdomtree.com/gb/media/wtma-vol-proof-proxy-form-adjourned-meeting

Holders of the Affected Securities should note that a duly completed voting instructions already made in respect of the Original Meeting will NOT continue to be valid for the Adjourned Meeting. Holders of the Affected Securities should therefore not rely on any voting instructions already made in respect of the Original Meeting and should therefore make arrangements to vote again on the matters being considered, in order to participate in the Adjourned Meeting.

Holders of the Affected Securities are advised to check with any bank, securities broker or other intermediary through which they hold their Affected Securities when such intermediary would need to receive instructions from a holder of Affected Securities in order for such holder of Affected Securities to participate in the Adjourned Meeting by the deadlines specified in this circular. The deadlines set by any such intermediary and each ICSD for the submission instructions will be earlier than the relevant deadlines specified in the circular.

In relation to the delivery instructions or obtaining voting certificates or otherwise making arrangements for the giving of voting instructions, in each case through the ICSDs, holders of the Affected Securities should note the particular practice and policy of the relevant ICSDs, including any earlier deadlines set by such ICSD. The deadlines set by any intermediary or by the ICSDs will be earlier than the deadlines set out in the circular.

In accordance with normal practice, The Law Debenture Trust Corporation p.l.c., as trustee, expresses no opinion as to the merits of the Proposal, the terms of which were not negotiated by it. It has however authorised it to be stated that, on the basis of the information contained in the original circular and in this document (which it advises holders of Affected Securities to read carefully) it has no objection to the form in which the Proposal and Notice of Meeting are presented to holders of Affected Securities for their consideration.

Holders of the Affected Securities will be notified of the outcome of the Adjourned Meeting shortly thereafter.

New plan strengthens Alignment’s Arizona portfolio available to nearly 1.1 million Medicare beneficiaries across Maricopa, Pima and Santa Cruz counties

PHOENIX, Oct. 22, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced a new Medicare Advantage plan for Pima County beginning Jan. 1, 2027, offering Pima County seniors access to low-cost coverage, local providers, bilingual support and coordinated care designed to help them stay healthy and independent. With the addition of Alignment Health ONE (HMO), Alignment Health Plan will now offer seven Medicare Advantage plans across Maricopa, Pima and Santa Cruz counties, which are home to nearly 1.1 million Medicare beneficiaries, according to data from the Centers for Medicare & Medicaid Services¹.

Alignment Health ONE (HMO) is also available as Alignment Health UNICO, a community-focused plan for Hispanic seniors that offers bilingual services, a low maximum out-of-pocket limit, a $2,500 dental allowance and a monthly allowance for groceries and other health-related needs.

With seven Medicare Advantage plans and a network of more than 15,000 primary care physicians and specialists, Alignment continues to expand its presence across Arizona while giving seniors more options to choose coverage that fits their health and financial needs. Plans include a variety of options designed to meet the diverse needs of Medicare beneficiaries, with offerings that emphasize affordability, personalized care and support for chronic health conditions.

“Every senior deserves the peace of mind that comes from knowing they have access to quality care, trusted local providers and support when they need it most,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “That’s what we strive to deliver at Alignment: coordinated, personalized care that helps seniors feel supported and confident throughout their health journey.”

Access to Trusted Care Close to Home

Members have access to a broad network of primary care physicians, specialists, hospitals and community-based providers across Arizona, helping ensure care is available when and where it is needed.

• Suvida Healthcare in Maricopa and Pima counties. Members enrolled in designated plans can access Suvida Healthcare’s primary care providers and neighborhood centers in Phoenix and Tucson. Bilingual care teams include physicians, nurses, physical and mental health therapists, clinical pharmacists, dietitians and Suvida “Guías” (Spanish for “guides”).
• CareMore Health in Maricopa County. With expanded access in mind, Alignment is extending its CareMore Health relationship to give members more primary care choices and coordinated support for chronic conditions and specialty care.

Proven Quality and Member Experience

For 2027, Alignment’s Arizona HMO contract is rated 4 stars, reflecting Alignment’s consistent ability to deliver high-quality service and responsive care across communities in the state. Every year, Medicare evaluates plans based on a 5-star rating system.

Plans and Support Built Around Members

Alignment’s 2027 Arizona portfolio offers plan choices designed around members’ health and financial needs. Alignment Health ONE + Walgreens (HMO) plans continue across Maricopa, Pima and Santa Cruz counties, offering exclusive over-the-counter access through Walgreens, while Alignment Health Smart (HMO) offers members a monthly rebate toward their Medicare Part B premium. Qualifying members living with diabetes or certain heart conditions can also choose specialized plans with Essentials allowances for groceries and everyday health-related expenses².

Every Alignment member has access to a 24/7 concierge team that helps coordinate care, navigate benefits and connect members to the support they need. Depending on the plan, members may also enjoy benefits such as $0 copays on more than 10,000 prescribed medications, over-the-counter and grocery² allowances, fitness programs and in-home support.

At a time when many Arizona seniors are reevaluating their Medicare coverage options, Alignment continues to expand access to affordable plans, coordinated care and trusted provider relationships across the state.

Medicare’s Annual Enrollment Period runs Oct. 15 through Dec. 7, 2026, with coverage taking effect Jan. 1, 2027. To learn more about Alignment Health’s 2027 Medicare Advantage plans in Arizona, visit alignmenthealthplan.com or call 1-888-979-2247.³

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Media Contact:
Jerry Slowey
publicrelations@ahcusa.com

Y0141_27449EN_M

___________________

¹ Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2026 MA State/County Penetration
² Special supplemental benefits for the chronically ill (SSBCI)-qualifying chronic conditions include congestive heart failure (CHF), dementia, diabetes, and stroke. Other chronic conditions may apply. Medical records will be used to establish the member qualification. The benefits mentioned are a part of a special supplemental program for the chronically ill. Not all members qualify because other eligibility and coverage criteria also apply.
³ Alignment Health Plan is an HMO, HMO POS, HMO C-SNP, HMO D-SNP and PPO plan with a Medicare contract and a contract with the California, Nevada, North Carolina and Texas Medicaid programs. Enrollment in Alignment Health Plan depends on contract renewal. The benefit information provided is a summary, not a complete description of benefits. For more information, contact the plan. Call 1-888-979-2247 (TTY: 711), 8 a.m. to 8 p.m. Monday through Friday, for more information. Other providers are available in our network.

RANCHO CUCAMONGA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a technology- and data-driven supply chain and infrastructure provider for online retailers and brands, today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock.

The reverse stock split will become effective at 12:01 a.m. Eastern Time on October 26, 2026, and the Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on October 26, 2026 under the existing ticker symbol “IPW.”

The new CUSIP number for the Company’s common stock following the reverse stock split will be 46265P503.

As a result of the reverse stock split, every 12 shares of the Company’s issued and outstanding common stock will automatically be combined into one issued and outstanding share of common stock. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to receive a fractional share will receive cash in lieu thereof. Prior to the reverse split, there were a total of 6,394,999 shares of common stock outstanding. Following the reverse split, there will be a total of approximately 532,917 shares of common stock outstanding.

The Company is effectuating the reverse stock split to increase the per share trading price of the Company’s common stock to ensure the Company maintains compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The reverse stock split was approved by the Company’s board of directors and stockholders.

VStock Transfer, LLC is acting as the exchange agent and transfer agent for the reverse stock split. Registered stockholders holding pre-split shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, custodian or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes.

About iPower Inc.

iPower Inc. (Nasdaq: IPW) is a technology- and data-driven company executing a focused strategy at the intersection of AI infrastructure and real-world commerce. Building on its established e-commerce operations, technology platform and capital markets experience, the Company is expanding into AI infrastructure investments and related financing ecosystems. Through targeted investments in digital assets, infrastructure financing protocols and other AI-related opportunities, iPower seeks to participate in the growth of the compute, data center and infrastructure layers that support artificial intelligence. Leveraging its operating experience, ecosystem relationships and capital markets access, iPower is building a scalable business designed to generate durable long-term value.

For more information, please visit www.meetipower.com.

Forward-Looking Statements

All statements other than statements of historical fact in this press release are forward-looking statements. Such statements involve known and unknown risks and uncertainties and are based on current expectations and projections. Actual results may differ materially from those set forth herein. iPower undertakes no obligation to update forward-looking statements except as required by law. Investors are encouraged to review iPower’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

Media & Investor Contact

IPW.IR@meetipower.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — Flutter Entertainment (“Flutter”) (NYSE: FLUT), the leading online sports betting and iGaming operator, today announced that it will release its third quarter 2026 update before US market open on November 4, 2026 at 7:00 a.m. ET (12:00 p.m. GMT). All related materials will be available through the “Investors” section of the Flutter website at www.flutter.com.

Flutter management will host a conference call on November 4, 2026 at 8:30 a.m. ET (1:30 p.m. GMT) to review the results and be available for questions, with access via webcast and telephone.

A public audio webcast of management’s call and the related Q&A can be accessed by registering here or via www.flutter.com/investors. For those unable to listen to the live broadcast, a replay will be available approximately one hour after conclusion of the call.

Analysts and investors who wish to participate in the live conference call must do so by dialling any of the numbers below and using meeting ID 481 500 392. Please dial in 10 minutes before the conference call begins.

+1 833 461 5787 (North America)
+44 117 389 0104 (United Kingdom)
+353 1800 851 901 (Ireland)
+61 1800 849 752 (Australia)
+1 585 542 9983 (International)

About Flutter Entertainment plc

Flutter is the world’s leading online sports betting and iGaming operator, with a market leading position in the US and across the world. Our ambition is to leverage our size and our challenger mindset to change our industry for the better. By Changing the Game, we believe we can deliver long-term growth while promoting a positive, sustainable future for all our stakeholders. We are well-placed to do so through the distinctive, global advantages of the Flutter Edge, which gives our brands access to group-wide benefits, as well as our clear vision for sustainability through our Positive Impact Plan.

Flutter operates a diverse portfolio of leading online sports betting and iGaming brands including FanDuel, Sky Betting & Gaming, Sportsbet, PokerStars, Paddy Power, Sisal, Snai, tombola, Betfair, MaxBet, Adjarabet and Betnacional.

To learn more about Flutter, please visit our website at www.flutter.com.

Enquiries
Investor Relations: Investor.relations@flutter.com
Media Relations: corporatecomms@flutter.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

San Antonio, TX, Oct. 22, 2026 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm known for its thematic ETFs,[1] is pleased to announce that its actively managed defense and technology ETF, the U.S. Global Technology and Aerospace & Defense ETF (NYSE: WAR), is now listed on Peru’s Bolsa de Valores de Lima (BVL), the Lima Stock Exchange.

WAR becomes the fourth U.S. Global ETF available to investors in Peru, joining the U.S. Global Jets ETF (NYSE: JETS), which listed in Lima in December 2020; the U.S. Global GO GOLD and Precious Metal Miners ETF (NYSE: GOAU), which followed in December 2023; and the U.S. Global Sea to Sky Cargo ETF (NYSE: SEA), which listed in November 2024. Peru is also the first market outside the U.S. where WAR is available.

“Peru has been a great home for JETS, GOAU and SEA, and we’re excited to now give Peruvian investors access to what we believe is one of the most important investment themes of this decade,” says Frank Holmes, the Company’s CEO and Chief Investment Officer. “Countries around the world are rebuilding defenses, and more and more of that money is going toward drones, satellites, artificial intelligence (AI) and cybersecurity. WAR is designed to capture both sides of that story, the traditional defense manufacturers and the technology companies that make modern defense possible.”

Global Defense Spending Reaches Another Record

World military expenditure rose to an estimated $2.89 trillion in 2025, the 11th consecutive year of growth, according to the Stockholm International Peace Research Institute (SIPRI). Spending climbed to 2.5% of global gross domestic product (GDP), the highest share since 2009, with South America rising to $56.3 billion. ^[2]

Peru is investing in its own armed forces as well. The government’s proposed 2027 budget, now before Congress, allocates 11.66 billion soles ($3.47 billion) to defense, with the largest amount set aside for investment projects in years.[3]

A Dual Focus on Traditional and Cyber Defense

Launched in December 2024, the WAR ETF uses a Smart Beta 2.0, the Company’s quantamental investment process. The process starts by identifying long-term themes driven by government policy and technological change. It then screens companies on quantitative factors such as profitability, volatility and liquidity, and adds fundamental research to decide which companies to own. The ETF holds 29 companies from developed markets worldwide. As of September 30, 2026, aerospace and defense companies made up 50% of the portfolio, followed by semiconductors at 30%, cybersecurity at 10% and data centers at 10%.

“I’ve always said that government policies are a precursor to change, and defense budgets are one of the clearest examples,” Mr. Holmes continues. “When governments commit to multi-year spending, that money flows to the companies building the equipment and the technology.”

A More Connected Regional Market

The listing comes as Peru’s capital markets become more closely linked with those of its neighbors. In April 2026, the BVL completed its move to the shared trading platform operated by Nuam, the regional exchange group that also runs the stock exchanges in Santiago, Chile, and Bogotá, Colombia.[4]

To learn more about the U.S. Global Technology and Aerospace & Defense ETF (NYSE: WAR), view the fact sheet and the Spanish-language investment case.

Follow U.S. Global Investors on X by clicking here.

Subscribe to U.S. Global Investors’ YouTube channel by clicking here.

About U.S. Global Investors, Inc.

The story of U.S. Global Investors goes back more than 50 years when it began as an investment club. Today, U.S. Global Investors, Inc. (www.usfunds.com) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San Antonio, Texas, the Company provides money management and other services to U.S. Global Investors Funds and U.S. Global ETFs.

####

Forward-Looking Statements and Disclosure

Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory and summary prospectus by visiting www.usglobaletfs.com. Read it carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the funds. Brokerage commissions will reduce returns. Because the funds concentrate their investments in specific industries, the funds may be subject to greater risks and fluctuations than a portfolio representing a broader range of industries. The funds are non-diversified, meaning they may concentrate more of their assets in a smaller number of issuers than diversified funds.

WAR: The ETF is actively managed and there is no guarantee the investment objective will be met. The ETF is new and has a limited operating history to evaluate. The ETF’s concentration in the securities of a particular industry, namely Aerospace and Defense, Cybersecurity and Semiconductor industries, as well as geographic concentration may cause it to be more susceptible to greater fluctuations in share price and volatility due to adverse events that affect the ETF’s investments.

Aerospace and Defense companies are subject to numerous risks, including fierce competition, adverse political, economic and governmental developments, and substantial research and development costs. Aerospace and defense companies rely heavily on the U.S. Government, political support and demand for their products and services.

Companies in the cybersecurity field face intense competition, both domestically and internationally, which may have an adverse effect on profit margins. The products of cybersecurity companies may face obsolescence due to rapid technological development. Companies in the cybersecurity field are heavily dependent on patent and intellectual property rights.

Competitive pressures may have a significant effect on the financial condition of semiconductor companies and may become increasingly subject to aggressive pricing, which hampers profitability. Semiconductor companies typically face high capital costs and can be highly cyclical, which may cause the operating results to vary significantly. The stock prices of companies in the semiconductor sector have been and likely will continue to be extremely volatile.

Investments in the securities of non-U.S. issuers may subject the ETF to more volatility and less liquidity due to currency fluctuations, political instability, economic and geographic events. Emerging markets may pose additional risks and be more volatile due to less information, limited government oversight and lack of uniform standards.

GOAU: Gold, precious metals, and precious minerals funds may be susceptible to adverse economic, political, or regulatory developments due to concentrating in a single theme. The prices of gold, precious metals, and precious minerals are subject to substantial price fluctuations over short periods of time and may be affected by unpredicted international monetary and political policies. We suggest investing no more than 5% to 10% of your portfolio in these sectors.

JETS: Airline companies may be adversely affected by a downturn in economic conditions that can result in decreased demand for air travel and may also be significantly affected by changes in fuel prices, labor relations and insurance costs.

SEA: Cargo companies may be adversely affected by downturn in economic conditions that can result in decreased demand for sea shipping and freight.

Smart beta 2.0 aims to combine the benefits of passive investing and the advantages of active investing strategies.

Distributed by Quasar Distributors, LLC. U.S. Global Investors is the investment adviser to WAR, JETS, GOAU and SEA.

---

[1] Registration does not imply a certain level of skill or training.
[2] Stockholm International Peace Research Institute (SIPRI). (2026, April). Trends in world military expenditure, 2025. https://www.sipri.org/publications/2026/sipri-fact-sheets/trends-world-military-expenditure-2025
[3] Defensa.com. (2026, September). Gobierno del Perú presenta proyecto presupuesto de Defensa 2027: 3.470 millones de dólares, un 26,5% más que en 2026 y la mayor cifra de inversión en años. https://www.defensa.com/peru/gobierno-peru-presenta-proyecto-presupuesto-defensa-2027-3-470-5 
[4] Bloomberg. (2026, August 10). Integración de bolsas de Santiago, Colombia y Lima da un nuevo paso para estar lista en 2027. https://www.bloomberglinea.com/mercados/integracion-de-bolsas-de-santiago-colombia-y-lima-da-un-nuevo-paso-para-estar-lista-en-2027/

CONTACT: Holly Schoenfeldt
U.S. Global Investors, Inc.
210.308.1268
hschoenfeldt@usfunds.com

Octopus AIM VCT plc

Purchase of Own Securities and Total Voting Rights

Octopus AIM VCT plc (the ‘Company’) announces that on 22 October 2026 the Company purchased for cancellation 1,300,158 ordinary shares of 1p each at a price of 38.2883p per share.

Following this transaction, the issued share capital and total voting rights of the Company will be 248,349,415 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Octopus AIM VCT 2 plc

Purchase of Own Securities and Total Voting Rights

Octopus AIM VCT 2 plc (the ‘Company’) announces that on 22 October 2026 the Company purchased for cancellation 1,821,330 ordinary shares of 0.01p each at a price of 30.6618p per share.

Following this transaction, the issued share capital and total voting rights of the Company will be 216,899,547 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Andrew Humphries
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800BW27BKJCI35L17

Revenue Grew 66% to $4.8 Million; Gross Profit Turned Positive at $0.4 Million

MOCKSVILLE, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), the only low nicotine tobacco company in the world, today announced select, preliminary and unaudited financial results and operating metrics for the third quarter ended September 30, 2026. The company anticipates releasing third quarter 2026 earnings on or before November 13, 2026, and will host a conference call for investors and financial analysts. The final date and details of the conference call will separately be released.

Preliminary Results

Preliminary unaudited financial results reflect continuing operations, excluding discontinued operations. All figures reported below are preliminary and subject to change.

• The Company expects third quarter 2026 net revenues of approximately $4.8 million compared with $2.9 million in the second quarter of 2026, an increase of 66%.
• The Company expects third quarter 2026 gross profit of approximately $0.4 million, compared to a loss of $(0.3) million in the second quarter of 2026.
• The company expects third quarter of 2026 operating expenses of $3.0 million, consistent with the second quarter of 2026.
• The company expects third quarter of 2026 operating loss of $2.6 million, compared to $3.3 million in the second quarter of 2026.
• The company expects third quarter of 2026 net loss of $2.6 million, compared to net loss of $3.3 million in the second quarter of 2026.
• The company expects third quarter of 2026 adjusted EBITDA loss of $2.2 million, compared to a loss of $3.5 million in the second quarter of 2026.
• Common shares outstanding as of October 22, 2026 are 3,416,441 and no warrants remain outstanding.
• Cash and equivalents were $3.9 million at quarter end.

“The third quarter marked another period of disciplined execution as we continued to increase consumer awareness and strengthen the commercial foundation for our Pinnacle VLN^® and 22^nd Century VLN^® low nicotine cigarettes,” said Larry Firestone, Chief Executive Officer of 22nd Century Group. “At retail, the growth in our same-store sales reports for Q3 2026 compared to Q2 2026 for the Pinnacle brand, both Pinnacle VLN^® and Pinnacle Pure cigarette products reinforced our belief that the market is looking for alternatives that change their smoking practice.”

Firestone added, “Today’s consumers are demonstrating through their early adoption of our VLN^® low nicotine cigarettes that a path to a low nicotine category in the market is being developed. It is our anticipation that multiple brands will adopt and carry a VLN^® branded set of sku’s in the future to pair with their standard brands. We believe that the future of smoking will include a low nicotine cigarette category of which we are the first and only player at the moment. The future of smoking is here. It’s VLN^®.”

Preliminary Financial Information

This news release includes financial information that is preliminary and has been prepared internally by management, and has not been audited, reviewed or compiled by our independent registered public accounting firm. 22^nd Century Group’s actual results remain subject to the completion of management’s final review and other closing and audit procedures and may differ materially from such financial information included in this news release due to the completion of our financial closing procedures, audit procedures and final adjustments. These preliminary estimates are not a comprehensive statement of our financial results for the third quarter 2026 and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Accordingly, you should not place undue reliance on these preliminary financial results.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship product, the VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN^® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

VLN^® and Helps You Smoke Less^® are registered trademarks of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com and pinnaclevln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Notes regarding Non-GAAP Financial Information

In addition to the Company’s reported results in accordance with generally accepted accounting principles in the United States of America (“GAAP”), the Company provides EBITDA and Adjusted EBITDA.

In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.

The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company’s measurement of Adjusted EBITDA may not be comparable to those of other companies.

Investor Relations & Media Contact
Daniel Otto  
Chief Financial Officer & Investor Relations   
22nd Century Group   
investorrelations@xxiicentury.com

• TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.
• Favorable safety profile, and generally comparable to placebo.
• Plan to submit supplemental BLA to the U.S. FDA in Q4 2026 for full approval expected in 2027.
• Investor webcast is scheduled for October 22 at 4:30 pm EDT.

BRISBANE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy (IgAN) at risk for disease progression was presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2026 and simultaneously published in The New England Journal of Medicine.

ORIGIN 3 met the primary endpoint of statistically significant proteinuria reduction at 36 weeks. In the final efficacy analysis, TRUTAKNA achieved statistical significance in all prespecified endpoints.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6f52e3a8-5843-4d89-a51b-a1344e2a52b3

TRUTAKNA also achieved statistically significant reductions in urine-protein to creatinine ratio, galactose-deficient IgA1, and hematuria. TRUTAKNA was well tolerated with a favorable safety profile generally comparable to placebo, consistent with previous safety data from the ORIGIN program.¹ Adverse events occurred in 160/214 patients (75%) on TRUTAKNA and 167/214 on placebo (78%). The rate of serious adverse events in the TRUTAKNA group was 7% compared with 15% in the placebo group. Infection rates were similar between TRUTAKNA (51.4%) and placebo groups (52.3%), and no clinically relevant hypogammaglobulinemia or opportunistic infections were observed. There was 1 death in the placebo group and no deaths in the TRUTAKNA group. No clinically meaningful effect of anti-drug antibodies on efficacy or overall safety was identified.

“I have spent my career caring for people with IgAN, and for most of that time, our conversations were about the limited treatment options,” said Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine, University of Leicester. “The ORIGIN 3 final efficacy results have the potential to change those conversations. In the study, TRUTAKNA achieved a physiologic rate of eGFR loss compared to the pathologic rate observed with placebo and significantly reduced the risk of composite kidney disease progression events, reflecting the potential for disease modification and kidney protection in IgAN. These results, combined with a safety profile comparable to placebo, represent a meaningful advance for patients.”

“ORIGIN 3 represents an important innovation in IgAN clinical development through our alignment with the FDA on an earlier final efficacy analysis. As a physician, I value the ability to offer patients randomized to placebo an earlier opportunity to transition to open-label active treatment, while generating a robust dataset. With the strength of the clinical data package, TRUTAKNA has the potential to transform the treatment landscape,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We plan to submit the supplemental BLA in the fourth quarter of this year, and we look forward to potential FDA full approval of TRUTAKNA in 2027. We reiterate our gratitude to the patients, investigators, employees, and collaborators who have helped us to deliver TRUTAKNA to patients in need.”

The Company will host an investor call and webcast to discuss the trial results at 4:30 PM EST on October 22. To register, click here.

The live webcast will be available on the Company’s Investor Calendar, with the recording and presentation available immediately following the event.

Indication

TRUTAKNA (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Important Safety Information

Contraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.

Warnings and Precautions

Immunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.

The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.

Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).

Use in Specific Populations

Pregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.

Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see full Prescribing Information for additional Important Safety Information.

About TRUTAKNA (atacicept-vymj)

TRUTAKNA, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL.² BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology. In IgAN, activated B cells produce both the antigen and associated antibodies that result in the production of damaging IgA immune complexes. The overlapping roles of BAFF and APRIL in activating B cells support the potential for TRUTAKNA as a disease-modifying therapy.³ TRUTAKNA is self-administered as an at-home, small-volume (1 ml), 150 mg once-weekly autoinjector.

TRUTAKNA TRU SUPPORT™ Patient Support Program

We are dedicated to ensuring that eligible IgAN patients can access the first approved therapy that targets both BAFF and APRIL. TRUTAKNA TRU SUPPORT, our patient support program, offers insurance coverage assistance, financial assistance options for eligible patients, and educational resources designed to support patient access and care. Eligible commercially insured patients may pay as little as $0 out of pocket through our copay assistance program. More information will be available on www.veratx.com.

About IgAN

IgAN is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney disease and kidney failure worldwide.^3,4 Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between 30 and 40 years of age.^5,6 Over time, IgAN can lead to irreversible kidney damage and may ultimately require dialysis or kidney transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.⁴

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the timing of the supplemental BLA submission to the FDA as well as full approval of TRUTAKNA by the FDA; the potential for the FDA to grant full approval to TRUTAKNA; the potential for TRUTAKNA to achieve results that reflect disease modification and kidney protection in IgAN; the potential for TRUTAKNA to represent a meaningful advance for patients; the ability for ORIGIN 3 to represent an important innovation in IgAN clinical development; the ability for TRUTAKNA to transform the treatment landscape; the potential for TRUTAKNA to be a disease-modifying therapy; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

References

1. Lafayette R, Barbour SJ, Brenner RM, et al. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N Engl J Med. 2026;394(7):647-657. doi:10.1056/NEJMoa2510198.

2. TRUTAKNA™ [Prescribing Information]. Brisbane, CA: Vera Therapeutics, Inc; July 2026

3. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. Published 2024 Feb 1. doi:10.3389/fneph.2023.1346769

4. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135

5. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665

6. Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol. 2019;30(5):866-876. doi:10.1681/ASN.2018101017

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com